Ebdarokimab

依若奇单抗

Report date: 2026/02/10 20:00:22

Base Information

Drug NameEbdarokimab
Drug Alias Name爱达罗AK-101AK101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitorsInterleukin-12 subunit beta inhibitors
TargetsInterleukin-12Interleukin-23Interleukin-12 subunit beta
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2025/04/15
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncZhongshan Akeso Biopharma Co Ltd
Inactive CompaniesAkeso Tiancheng Inc
Active IndicationsPlaque psoriasisPsoriasisColitis, Ulcerative
Inactive IndicationsCrohn DiseaseArthritis, Psoriatic

Other Information

ATC CodeN/A
Related LinksN/A